Release Date: November 20, 2017
Letter of Intent Receipt Date: December 20, 2017
Application Receipt Date: March 23, 2018 (by 5pm local time for the submitting HIPC site)
Primary Review Completed: April 16, 2018
Rebuttal Receipt Date: May 4, 2018
Secondary Review Completed: May 18, 2018
Earliest Anticipated Award Date: June 1, 2018
The purpose of this renewal program is to promote U.S.-India collaborative research on human immunophenotyping studies (see definition under “Research Objectives” section), in collaboration with investigators of the NIAID Human Immunology Project Consortium (HIPC, www.immuneprofiling.org). HIPC was established in 2010 and renewed in 2015 and 2016 by the NIAID Division of Allergy, Immunology, and Transplantation (DAIT) as part of the overall NIAID focus on human immunology. The current HIPC program is co-sponsored by the NIAID Division of AIDS (DAIDS) and the Division of Microbiology and Infectious Diseases (DMID), and is composed of nine cooperative agreement awards to investigators throughout the U.S. (see list below of Eligible HIPC Investigators).
This program is being conducted under the auspices of the Indo-U.S. Vaccine Action Program (VAP) – a bilateral program of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) within the Department of Health and Human Services, United States (U.S.); and the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India; in conjunction with HIPC. Applications are invited from HIPC investigators to work together with investigators in India to perform collaborative research projects in the area of human immunophenotyping. U.S. investigators not currently supported under HIPC also are eligible to apply to this funding opportunity by establishing a collaboration with a HIPC investigator. Awards will be funded jointly, by NIAID via the HIPC Infrastructure and Opportunities Fund, and by the Government of India via DBT.